Pronota rais­es an addi­tion­al EUR 1.5 mil­lion in a final close of its Series B financ­ing total­ing EUR 7.9 mil­lion

Ghent, Belgium, 17th May 2010 – Pronota NV today announced that it has raised an addi­tion­al EUR 1.5 mil­lion in the final close of its Series B financ­ing. The financ­ing has been sub­scribed by MedSciences Capital, the ven­ture cap­i­tal arm of Kempen & Co, which is a spe­cial­ized Dutch mer­chant bank. Pronota has raised a total of EUR 7.9 mil­lion in its Series B round, which has been sub­scribed by pre­mier life sci­ences investors such as Gimv, Biotech Fund Flanders, LSP, JJDC, KBC Private Equity, VIB, MP Healthcare Venture Management Inc., Baekeland Fund and MedSciences Capital. Pronota is using the pro­ceeds of the Series B financ­ing to push for­ward its diag­nos­tic devel­op­ment pro­grams in the car­dio-renal area, pre-eclamp­sia, sep­sis, and ovar­i­an can­cer.

The results obtained so far in its car­dio-renal and oth­er pro­grams pro­vide exten­sive val­i­da­tion of Pronota’s tech­nol­o­gy. Pronota now address­es a range of sig­nif­i­cant com­mer­cial oppor­tu­ni­ties, and is aim­ing to have its first prod­uct ready for launch in 2012.

Leave a Reply

Your email address will not be published. Required fields are marked *